NCT05970432

A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of TQH2722 Injection in Subjects With Moderate to Severe Atopic Dermatitis

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 160 (estimated)
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This phase II clinical trials is multicenter, randomized, double-blind, placebo-controlled to assess the effectiveness and safety of TQH2722 injection in the treatment of subjects with moderate to severe atopic dermatitis.

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	TQH2722 injection 300mg-150mg	TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.
DRUG	TQH2722 injection 600mg-300mg	TQH2722 injection is a fully human monoclonal antibody that thereby interfering with the signal cascade.
DRUG	TQH2722 injection 900mg-450mg	TQH2722 injection is a fully human monoclonal antibody that thereby interfering with the signal cascade.
DRUG	TQH2722 injection matching Placebo	Placebo without active substance.

Timeline

• Start date: 2023-06-19
• Primary completion: 2024-03-01
• Completion: 2024-03-01
• First posted: 2023-08-01
• Last updated: 2023-08-01

Locations

32 sites across 1 country: China